ALBAN (GETUG-AFU 37): A phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladder cancer (NMIBC)
{{output}}
Background: Standard treatment for high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT) is intravesical instillation with Bacillus Calmette-Guérin (BCG) (induction and maint... ...
